S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
Comparing Asciminib and Ponatinib Profiles
Elias Jabbour contrasts asciminib (studied vs bosutinib) and ponatinib (phase 2/OPTIC), noting mutation-driven resistance and combination rationale.
Play episode from 06:50
Transcript
